II. Indications: Neuraminidase Inhibitor

III. Contraindications

IV. Precautions

V. Dosing

  1. Contraindicated in bronchospastic disease
  2. Take the first 2 doses at least 2 hours apart (first day)
  3. Treatment (age 7 years and older)
    1. Dose: 10 mg (2 inhalations) twice daily for 5 days
  4. Prevention (age 5 years and older)
    1. Dose: 10 mg (1 inhalation) daily for 10 days

VI. Adverse effects

  1. Bronchospasm (with Relenza only)
  2. Neuropsychiatric effects
  3. Stevens-Johnson Syndrome (rare)

VII. Safety

  1. Considered safe in pregnancy
  2. Considered safe in Lactation

Images: Related links to external sites (from Bing)

Related Studies

Ontology: Zanamivir (C0216660)

Definition (NCI) A sialic acid-analogue neuraminidase inhibitor with antiviral activity. Administered into the respiratory tract by aerosol inhalation, zanamivir selectively binds to and inhibits influenza A and B virus neuraminidase-mediated cleavage of sialic acid residues in host cell membrane-bound glycoprotein receptors for influenza viruses, preventing the release of progeny viruses from host cell surfaces and, so, further viral replication.
Definition (NCI_NCI-GLOSS) A drug used to prevent and to treat influenza virus infections. It blocks the release of the virus from infected cells. It is a type of antiviral agent.
Definition (MSH) A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D053243
SnomedCT 116100000, 387010007
LNC LP101309-5, MTHU047708
English 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic Acid, 5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic Acid, GANA, Zanamivir, 5-acetylamino-4-guanidino-6-(1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid, Acid, 4-Guanidino-2-Deoxy-2,3-Didehydro-N-Acetylneuraminic, 2,3-Didehydro-2,4-Dideoxy-4-Guanidino-N-Acetyl-D-Neuraminic Acid, 2,3-Didehydro-2,4-Dideoxy-4-Guanidinyl-N-Acetylneuraminic Acid, 4 Guanidino 2 Deoxy 2,3 Didehydro N Acetylneuraminic Acid, 4 Guanidino Neu5Ac2en, 4-Guanidino-2,4-Dideoxy-2,3-Didehydro-N-Acetylneuraminic Acid, 4-Guanidino-2-Deoxy-2,3-Didehydro-N-Acetylneuraminic Acid, 5-Acetylamino-2,6-Anhydro-4-Guanidino-3,4,5-Trideoxy-D-Galacto-Non-Enoic Acid, 4-Guanidino-Neu5Ac2en, zanamivir, zanamivir (medication), ZANAMIVIR, Zanamivir [Chemical/Ingredient], Zanamivir (product), Zanamivir (substance)
Portuguese Zanamivir
Spanish Zanamivir, zanamivir (producto), zanamivir (sustancia), zanamivir
Russian ЗАНАМИВИР, 4-ГУАНИДИНО-2,4-ДИДЕЗОКСИ-2,3-ДИДЕГИДРО-N-АЦЕТИЛНЕЙРАМИНОВАЯ КИСЛОТА, ZANAMIVIR, 4-GUANIDINO-2,4-DIDEZOKSI-2,3-DIDEGIDRO-N-ATSETILNEIRAMINOVAIA KISLOTA
Italian Zanamivir
German 2,3-Didehydro-2,4-Dideoxy-4-Guanidino-N-Acetyl-D-Neuraminsäure, 4-Guanidino-2,4-Dideoxy-2,3-Didehydro-N-Acetylneuraminsäure, 4-Guanidino-2-Deoxy-2,3-Didehydro-N-Acetylneuraminsäure, 4-Guanidino-Neu5Ac2en, Zanamivir, 2,3-Didehydro-2,4-Dideoxy-4-Guanidinyl-N-Acetylneuraminsäure
French Zanamivir, Acide 5-acétamido-2,6-anhydro-4-guanidino-3,4,5-tridésoxy-D-glycéro-D-galacto-non-2-énonique, Acide N-acétyl-2,3-déhydro-2,4-didésoxy-4-guanidino-neuraminique
Finnish Tsanamiviiri
Czech zanamivir
Japanese ザナミビル
Swedish Zanamivir
Polish Zanamiwir

Ontology: Relenza (C0876148)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D053243
English Relenza, Biota Brand of Zanamivir, Glaxo Wellcome Brand of Zanamivir, GlaxoSmithKline Brand of Zanamivir, Zanamivir Biota Brand, Zanamivir GlaxoSmithKline Brand, relenza
German Relenza
Czech Relenza